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Perhaps the most pressing need in cancer therapeutics is to understand drug resistance. In this issue of
Cancer Cell, Hirata and colleagues show that melanoma-associated fibroblasts can drive resistance to the
BRAF inhibitor PLX4720 by stimulating matrix production/remodeling, and, consequently, survival signaling
in melanoma cells via b1-integrin, Src, and FAK.Melanoma accounts for around 4%–5%
of new cancer cases in the United States,
with incidence rates continuing to rise
(Siegel et al., 2015). A large fraction of
melanomas carry BRAFmutations. Treat-
ment of BRAF mutant melanoma with
BRAF kinase inhibitors has been associ-
ated with rapid initial tumor regression in
many patients, yielding median progres-
sion-free survival of around seven months
(Menzies and Long, 2014). However,
tumors almost always recur and are
refractory to further BRAF inhibitor
treatment. In this issue of Cancer Cell,
Hirata et al. (2015) report a non-cell auton-
omous mechanism of resistance to the
BRAF inhibitor PLX4720. They describe
a link between ‘‘paradoxical’’ drug-
induced activation of melanoma-associ-
ated fibroblasts (MAFs) in response to
PLX4720 and resistance in melanoma
cells. Importantly, they show that adding
MAFs in co-culture can foster resistance
in melanoma cells that are intrinsically
susceptible to the effects of PLX4720
when removed from the tumor and
cultured in isolation. This work beautifully
illustrates the need to investigate drug
resistance mechanisms in an appropriate
context and to consider the role of host
cells in the tumor microenvironment
in vivo.
Unraveling the complex and dynamic
relationship between tumor infiltrating
host cells, the extracellular matrix (ECM),
and tumor cells is important if we are to
fully understanding cancer progression
and mechanisms of therapeutic resis-
tance. Hirata et al. (2015) make excellent
use of recent advances in multi-photonintravital microscopy, coupling it to the
use of a fluorescence resonance energy
transfer (FRET)-based optical sensor to
read out activity of the ERK/MAP kinase
downstream of BRAF. They were able to
perform longitudinal dynamic imaging
with sub-cellular resolution in living tissue,
enabling detailed in niche analysis in
a more clinically relevant pre-clinical
context than cells in culture. Combining
these approaches, the authors interro-
gated the spatial localization of ERK
activity upon treatment with PLX4720
and correlated loss of response (or resis-
tance) with high stromal density (Figures
1A and 1B). Interestingly, whenmelanoma
cells were re-isolated from these tumors,
they retained their intrinsic sensitivity to
PLX4720, establishing that the tumor
microenvironment was able to provide a
‘‘safe haven’’ that protected cancer cells
from the effects of PLX4720 and fostered
the emergence of resistant cells.
Further co-culture experiments identified
enhanced matrix production and stiff-
ening induced by activated MAFs as
a trigger for stimulating the b1-integrin-
Src-FAK (focal adhesion kinase) signaling
pathway in response to PLX4720,
providing melanoma cells with an alterna-
tive route to sustain ERK activity and sur-
vive (Figure 1B). The plasticity of these
cancer cells to ‘‘re-wire’’ the signaling
pathways they depend on at relatively
short notice, in this case through utilizing
changes in the nature and composition
of the tumor microenvironment, may
represent a more widespread drug resis-
tance mechanism. This could also be
relevant to other molecularly targetedCancer Celtherapies for which emerging resistance
is a major clinical challenge.
FAK is a non-receptor protein tyrosine
kinase that regulates diverse cellular func-
tions, including adhesion, migration, inva-
sion, proliferation, and survival (McLean
et al., 2005). Hence, it is involved in a num-
ber of processes that can impact the ma-
lignant phenotype. Expression of FAK is
elevated in a number of human tumor
types (McLean et al., 2005), and inhibi-
tors targeting FAK kinase function are
currently undergoing clinical testing in
epithelial cancers (Roberts et al., 2008;
Shapiro et al., 2014). For example,
phase-1 dose escalation studies of the
FAK inhibitor GSK2256098 have found
single agent activity in a number of tumor
types, including melanoma (Soria et al.,
2012), providing evidence of some clinical
efficacy in this setting. Hirata et al. (2015)
show that combination of PLX4720 with
the FAK inhibitor PF562271 results in
enhanced anti-tumor activity over that of
either monotherapy alone in both synge-
neic melanomamodels or patient-derived
xenografts (Figure 1C). Unsurprisingly,
the dual targeting of BRAF and FAK was
not sufficient to induce complete tumor
regression, suggesting that, while this
combination may potentially have added
clinical benefit, it is unlikely to promote
the sought-after ‘‘cure’’. Analysis of tumor
samples from vemurafenib-resistant pa-
tients confirmed that there was often
increased fibroblastic stroma and matrix
remodelling once resistance to BRAF in-
hibitors had developed, implying that
this drug resistance mechanism may be
a reality in some patients. Thus, withl 27, April 13, 2015 ª2015 Elsevier Inc. 429
Figure 1. Paradoxical Activation of MAFs Promotes Resistance to BRAF Inhibition via FAK Signaling
(A) Heterogeneous BRAF mutant melanomas contain areas of high stromal density in which cancer cells and melanoma associated fibroblasts (MAFs) are found
proximal to each other.
(B) Treatment with PLX4720 produces a heterogeneous response. Cancer cells in areas of high stromal density become resistant to PLX4720 by re-activating
ERK through the b1-integrin-Src-FAK pathway due to enhanced MAF-dependent matrix deposition and remodeling. This is likely due to ‘‘paradoxical’’ activation
of MAFs by PLX4720.
(C) Combined BRAF-FAK/Src inhibition improves tumor response through inhibition of ERK activity and induction of apoptosis in melanoma cells that reside
within areas of high stromal density.
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Previewstargeted inhibitors of BRAF and FAK ki-
nase activities already in clinical use and
at an advanced stage of early phase clin-
ical development, respectively, it should
be tested whether this combination pro-
vides an extended period of disease sta-
bilization in patients with BRAF mutant
melanoma.
Regarding clinical context, success in
the treatment of melanoma may well
see a seismic shift in the next few years
with the clinical testing of approaches
to re-activate cytotoxic CD8 T cells
and induce anti-tumor immunity. Agents
that inhibit the immune checkpoint
blockade pathways, primarily pro-
grammed death-1 receptor (PD-1) and
cytotoxic T-lymphocyte-associated pro-
tein 4 (CTLA4), are showing impressive
clinical efficacy as single agents and
even more so when combined. A clinical
study combining these agents in patients
with advanced melanoma reported a
staggering 53% of patients exhibiting430 Cancer Cell 27, April 13, 2015 ª2015 Elsan objective response associated with a
greater than 80% reduction in tumor
burden (Wolchok et al., 2013). While this
gives great optimism, it is not yet a
‘‘magic bullet’’ in every case. The treat-
ment landscape for melanoma will
continue to develop, and it will be imper-
ative to identify potential biomarkers,
both phenotypic and molecular, that can
enable patient stratification and some
tailoring of therapy. The work of Hirata
et al. (2015) indicates that the combina-
tion of BRAF and FAK inhibitors may
well have a role with predicted efficacy
in tumors characterized by elevated
MAF infiltration, increased fibrous ECM,
and activated Src/FAK signaling, all of
which can be measured. Furthermore, it
will be interesting to determine if and in
which patients this combination could
be used alongside immune checkpoint
blockade therapies. An intriguing possi-
bility is that combined BRAF and FAK in-
hibitors may slow down the winning ofevier Inc.the ‘‘clone wars’’ by drug-resistant clones
long enough to permit a revitalized im-
mune system to have a curative effect.
Overall, the work presented by Hirata
et al. (2015) provides new insight into
how components of the tumor micro-
environment, namely MAFs in this case,
contribute to a ‘‘safe haven’’ in which
BRAF mutant melanoma cells can adapt
and evade therapy. It clearly demon-
strates the need to study multi-factorial
drug resistance mechanisms in the
context of the tumor microenvironment,
and, to this end, it shows the power of
imaging and quantifying pathway activ-
ities at the single-cell level over time in-
side complex and heterogenous tumor
tissue.
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The interaction between menin and oncogenic mixed lineage leukemia (MLL) fusion proteins is required for
leukemic transformation andmay represent a therapeutic opportunity. In this issue ofCancer Cell, Borkin and
colleagues describe the development of highly potent small-molecule inhibitors of this interaction that
reverse the leukemic phenotype and prolong survival in murine models of MLL-rearranged leukemia.Acute leukemias that harbor a rearrange-
ment of the mixed lineage leukemia gene
(MLL) are aggressive hematopoietic
malignancies that occur across all age
groups and develop as lymphoid,
myeloid, or biphenotypic disease. In in-
fants and children, MLL-rearranged leu-
kemias represent a poor risk category of
acute lymphoblastic leukemia. Adults
typically present with acute myeloid leu-
kemia that arises de novo or following
treatment with topoisomerase-II inhibitors
for an unrelated neoplastic disorder.
Chemotherapy is considered the stan-
dard of care, but treatment outcome is still
unsatisfactory with event-free survival
rates of approximately 50% for both pedi-
atric and adult patients (Neff and Arm-
strong, 2013). These data together with
the increasing population of older leuke-
mia patients not eligible for intensive
chemotherapy indicate a strong need for
novel less toxic treatment approaches.
Research over the last decade has sub-
stantially improved our understanding of
MLL-rearranged leukemogenesis and
disease biology. To date, more than 70
translocations are known that encode
dominant oncogenic fusion proteins
where MLL is fused to one of more than60 different partner proteins (Meyer
et al., 2013). Recent efforts have led to
the discovery of several potential molecu-
lar targets for therapeutic development.
The histone 3 lysine 79 methyltransferase
DOT1L and menin, a protein that interacts
directly with MLL-fusion proteins, repre-
sent two of the most well-characterized
candidates (Bernt et al., 2011; Yokoyama
et al., 2005). Both proteins are believed to
be required for MLL-fusion target gene
expression and transformation by MLL-
fusion proteins. Small-molecule DOT1L
inhibitors have recently been translated
to clinical trials (Daigle et al., 2013). In
this issue of Cancer Cell, Borkin et al.
(2015) describe the development of two
improved inhibitors of the menin-MLL
interaction that will hopefully enable
translation of this therapeutic approach
to clinical assessment.
Menin, the protein encoded by the mul-
tiple endocrine neoplasia 1 gene (Men1)
functions as a tumor suppressor in the
similarly-named familial syndrome but
contributes to MLL-rearranged leukemia
as a co-factor essential for leukemic
transformation (Yokoyama et al., 2005).
It interacts with the N-terminal part of
MLL, which is maintained in all MLL-fusion proteins, and is essential for MLL-
fusion-driven leukemogenesis. Inactiva-
tion of Men1 prevents leukemogenesis in
bone marrow progenitor cells ectopically
expressing MLL fusions (Chen et al.,
2006) and loss-of-function mutations in
the menin binding motif of MLL abrogate
leukemogenic transformation by MLL-
fusion proteins (Chen et al., 2006; Yo-
koyama et al., 2005). Menin is obligatory
for the interaction of MLL-fusion proteins
with LEDGF, a protein that facilitates
chromatin binding of the MLL complex
(Yokoyama and Cleary, 2008). Further-
more, the menin-MLL interaction is
required for the activation of MLL-fusion
target genes, such as Hoxa-cluster genes
andMeis1, which are pivotal for the devel-
opment of MLL-fusion-driven leukemia
(Yokoyama et al., 2005). However, reports
that the interaction between menin and
the wild-type MLL protein is required for
Hox gene expression in early hematopoi-
etic progenitors to maintain self-renewal
properties (Chen et al., 2006; Maillard
et al., 2009) raises the concern that thera-
peutic targeting of menin might lead to a
rapid attrition of hematopoietic stem cells,
thereby affecting normal hematopoiesis.
However a recent study by Li et al.l 27, April 13, 2015 ª2015 Elsevier Inc. 431
